Citations

Clear

3 citation(s) found for "Serzan, Michael".

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4
Taplin, Mary‐Ellen , Rumble, R. Bryan , Naqvi, Syed Arsalan Ahmed , Nahhat, Fouad , Dias, Mariane Sousa Fontes , Hope, Thomas A. , He, Huan, Hotte, Sebastién J. , Emamekhoo, Hamid , Celano, Paul, Kungel, Terry M. , Hentzen, Steve, Marzalik, Jacob S. , Parikh, Rahul A , Rumble, R Bryan , Nahhat, Fouad , Dias, Mariane Fontes , Hope, Thomas A , Hotte, Sebastien J , Emamekhoo, Hamid , Murad, M Hassan , Hentzen, Steve , Marzalik, Jacob S , Serzan, Michael Thomas , Riaz, Irbaz B , Taplin, Mary-Ellen , He, Huan, Murad, M. Hassan , Celano, Paul , Serzan, Michael , Riaz, Irbaz Bin

Mayo Clinic

Journal of Clinical Oncology | August 6, 2026 | Volume: 44 | Issue: 31 | Pages: No page available

10.1200/jco-26-01898 | PMID 42561262 Get It

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found on the ASCO Publications website .
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma
McKay, Rana R. , Serzan, Michael, Xie, Wanling, Braun, David A. , Wei, Xiao X. , Kyriakopoulos, Christos E. , Zakharia, Yousef , Maughan, Benjamin L. , Rose, Tracy, Mcdermott, David F, Braun, David , Wei, Xiao , Kyriakopoulos, Christos E , Zakharia, Yousef , Choueiri, Toni K , Xie, Wanling , McGregor, Bradley A. , Stadler, Walter M. , McDermott, David F. , Choueiri, Toni K.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 1, 2026 | Volume: 14 | Issue: 7 | Pages: e015501

10.1136/jitc-2026-015501 | PMID 42386345 Get It

Background Immune checkpoint inhibitor-based combinations represent the standard of care for advanced renal cell carcinoma. The OMNIVORE trial investigated a response-adaptive strategy, including treatment discontinuation in early nivolumab responders (Arm A) and salvage ipilimumab addition in non-responders (Arm B). Here we report outcomes with extended follow-up. Methods OMNIVORE was a phase II response-adaptive trial in which patients received induction nivolumab monotherapy. Patients achieving a confirmed complete or partial response discontinued nivolumab and entered observation (Arm A), while patients with stable disease or progressive disease received two doses of ipilimumab added to ongoing nivolumab (Arm B). This analysis characterizes long-term overall survival across the full study cohort and durability of response among patients who discontinued nivolumab following an early objective response. Results Of 83 patients who initiated treatment, 12 (14%) were allocated to Arm A and 57 (69%) to Arm B, with a median follow-up among living patients of 59.4 months (range 29.1–85.4 months) in Arm A and 31.4 months (range 4.6–62.6 months) in Arm B. The 3-year overall survival rate from nivolumab initiation was 64% (95% CI 51% to 74%) in the overall cohort, 83% (95% CI 48% to 96%) in Arm A, and 63% (95% CI 47% to 76%) in Arm B. Of the 12 Arm A patients, 6 (50%) remained off nivolumab at 1 year following treatment discontinuation, of whom 5 maintained responses beyond 43 months off therapy, with all remaining alive at last known follow-up, with overall survival ranging from 48.8 to 85.4 months from nivolumab initiation. Of the six patients who resumed treatment, only one achieved a durable complete response remaining on treatment at 83.2 months from nivolumab initiation. All 57 Arm B patients discontinued treatment with a median treatment duration of 3.7 months (range 1–24.8 months) and a median progression-free survival from nivolumab plus ipilimumab initiation of 4.6 months (95% CI 2.7 to 6.5 months). Conclusions With extended follow-up, a meaningful subset of patients achieving an early objective response to nivolumab maintained prolonged treatment-free survival following a short course of treatment. Salvage ipilimumab in nivolumab non-responders demonstrated limited benefit, reinforcing that upfront concurrent dual checkpoint blockade remains the preferred approach. Trial registration number NCT03203473 .
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1
Taplin, Mary-Ellen, Riaz, Irbaz Bin , Rumble, R. Bryan , Naqvi, Syed Arsalan Ahmed , Hope, MD Thomas A., Dias, Mariane Fontes , He, Huan, Hotte, Sebastién J. , Emamekhoo, Hamid, Murad, M. Hassan, Celano, Paul , Kungel, Terry M. , Hentzen, Steve, Serzan, Michael , Parikh, Rahul A., Murad, M. Hassan , Hope, Thomas A. , Emamekhoo, Hamid , Dias, Mariane Sousa Fontes , Hope, Thomas A , Emamekhoo, Hamid , Murad, M Hassan , Serzan, Michael Thomas , Parikh, Rahul A , He, Huan , Riaz, Irbaz B , Hotte, Sebastien J , Rumble, R Bryan , Taplin, Mary‐Ellen , Kungel, Terry

Mayo Clinic

Journal of Clinical Oncology | January 20, 2026 | Volume: 44 | Issue: 6 | Pages: No page available

10.1200/jco-25-02693 | PMID 41557978 Get It

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found at www.asco.org/genitourinary-cancer-guidelines .